Biotech IV Monitor

SRRK — Scholar Rock Holding Corporation

$5.7B market cap · 0 upcoming readouts tracked

Clinical trial readout dates for Scholar Rock Holding Corporation, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

Market cap$5.7B
Cash & investments$414M~4 quarters at last loss rate
Recent 8-K filings1latest 2026-11-10

In progress, no date published

Phase 2 Apitegromab
Spinal muscular atrophy (SMA)
date not published
Trial Planned
Phase 2 SRK-439 with apitegromab
Obesity
date not published
Ongoing

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 2 Apitegromab (SRK-015)
Spinal muscular atrophy (SMA)
January 19, 2021
Ongoing

Cash position

Scholar Rock Holding Corporation reported $414M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-10). Its net loss for that quarter was $107M; at that rate the cash would last about 4 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Reg FD Disclosure — often a data announcement2026-11-10

Companies working on similar indications

Discussion

No messages yet. If you follow SRRK, you can start the conversation.
Track SRRK in real time
See live implied volatility for SRRK and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on SRRK
Contact — questions or corrections about SRRK: dukeupt@gmail.com